Arrowstreet Capital’s NEVRO CORP. NVRO Stock Holding History

Arrowstreet Capital’s Portfolio NVRO Stock Details NVRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32,906	Closed	-$4.59M	–	2287
2021 Q1	$4.59M	Buy	32,906 +26,506	+414%	+$4.33M	0.01%	1211
2020 Q4	$1.11M	Buy	+6,400	New	+$1.04M	﹤0.01%	1797
2020 Q2	–	Sell	-27,489	Closed	-$2.75M	–	2488
2020 Q1	$2.75M	Buy	+27,489	New	+$3.31M	0.01%	948

Other funds holding NVRO

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Arrowstreet Capital's NVRO Position: Q2 2021 in Review

Arrowstreet Capital sold out of NEVRO CORP. (NVRO) in Q2 2021, closing a stake of 32,906 shares — an estimated $4.59M sold.

Arrowstreet Capital first reported a position in NVRO in Q1 2020 and held it in 3 quarters. The position peaked at $4.59M in Q1 2021. 207 funds tracked by Wall St. Rank hold NVRO as of Q2 2021.

Arrowstreet Capital reported no remaining NEVRO CORP. position as of Q2 2021 after selling out during the quarter.
Arrowstreet Capital sold 32,906 NEVRO CORP. shares in Q2 2021, an estimated $4.59M.
Arrowstreet Capital first reported a position in NEVRO CORP. in Q1 2020 and held it in 3 quarters.
Arrowstreet Capital's NEVRO CORP. position peaked at $4.59M in Q1 2021.
207 funds tracked by Wall St. Rank held NEVRO CORP. as of Q2 2021.

Based on Arrowstreet Capital's 13F filing for Q2 2021, filed 13 Aug 2021.